Rather than an inescapable part of
The FDA’s decision was the culmination of a string of high-profile animal studies that tried—and succeeded—in reversing tissue decay in aged rodents. The blood of the young, metformin, and senolytics—drugs that wipe out unhealthy “leaky” old cells like a biological spring cleaning—rebooted the faltering bones, hearts and brains of those rodent senior citizens. And they didn’t just get healthier—many also lived longer.
With many treatments entering human trials for aging-associated diseases and unfaltering interest (and funding) from the private sector, momentum in the field shows no signs of stopping. Are we on the verge of beating aging?
Not so fast, says a new study by Drs. Paul Nelson and Joanna Masel at the University of Arizona.
